A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. - Abstract - Europe PMC

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Axial spondyloarthritis - The Lancet

Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89).

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study - Pavelka - 2020 - ACR Open Rheumatology - Wiley Online Library

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.

Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice – topic of

TNF Inhibitor Therapy, Ankylosing Spondylitis

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data - Baraliakos - 2005 - Arthritis Care & Research - Wiley Online Library

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.